Company: SRPT
Filing Date: 2025-03-03
Form Type: S-3ASR
Source: 0001193125-25-044088
Chunk: 8

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-03-03
Form: S-3ASR
Chunk 8
---
 prospectus is a part or in other filings we make with the Commission under the Exchange Act, which are incorporated by reference herein.

4

GENERAL DESCRIPTION OF SECURITIES WE MAY SELL We or any selling securityholder may offer shares of our common stock and preferred stock, various series of debt securities and warrants to purchase any of such securities, either individually or in units, from time to time under this prospectus, together with any applicable prospectus supplement and related free writing prospectus, in amounts, at prices and on terms to be determined by market conditions at the time of offering. If we issue any debt securities at a discount from their original stated principal amount, then, for purposes of calculating the total dollar amount of all securities issued under this prospectus, we will treat the initial offering price of the debt securities as the total original principal amount of the debt securities. Each time we or any selling securityholder offer securities under this prospectus, we will provide offerees with a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities being offered, including, to the extent applicable:

| • |     | designation or classification; |

| • |     | aggregate principal amount or aggregate offering price; |

| • |     | maturity, if applicable; |

| • |     | original issue discount, if any; |

| • |     | rates and times of payment of interest or dividends, if any; |

| • |     | conversion or exchange prices or rates, if any, and if applicable, any provisions for changes to or adjustments               
 in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; |

| • |     | ranking; |

| • |     | restrictive covenants, if any; |

| • |     | voting or other rights, if any; and |

| • |     | important United States federal income tax considerations. |

The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. We or any selling securityholder may sell the securities to or through underwriters, dealers or agents or directly to purchasers or as otherwise set forth below under “Plan